Scinai Immunotherapeutics
SCNI
10 hedge funds and large institutions have $2.27M invested in Scinai Immunotherapeutics in 2019 Q1 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
11% more funds holding
Funds holding: 9 → 10 (+1)
0.1% less ownership
Funds ownership: 2.42% → 2.31% (-0.1%)
59% less capital inflows, than outflows
Capital inflows: $57.2K | Capital outflows: $139K
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Edge Wealth Management
New York
|
+$52K |
| 2 |
Morgan Stanley
New York
|
+$5.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mariner
Overland Park,
Kansas
|
-$129K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$10.4K |
SCNI Hedge Fund Activity: Q1 2019 in Review
10 of the 4,634 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q1 2019, worth a combined $2.27M — up 6.4% from $2.13M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new SCNI positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Edge Wealth Management, opening a new position worth an estimated $52K. The largest seller was Mariner, exiting entirely with an estimated $129K sold.
- 10 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q1 2019, up from 9 in Q4 2018.
- Funds reported $2.27M of Scinai Immunotherapeutics stock for Q1 2019, up 6.4% quarter-over-quarter.
- 2 funds opened new Scinai Immunotherapeutics positions in Q1 2019 and 1 closed out, a net change of +1 holder.
- The largest Scinai Immunotherapeutics buyer in Q1 2019 was Edge Wealth Management, an estimated $52K added.
- The largest Scinai Immunotherapeutics seller in Q1 2019 was Mariner, an estimated $129K sold.
Based on aggregated 13F filings for Q1 2019.